Esperion Therapeutics | ESPR - Current Assets


Esperion Therapeutics reported $459.46M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
AbbVie USD 33.53B 4.47B Mar/2026
Alnylam Pharmaceuticals USD 4.22B 168.65M Mar/2026
Alterity Therapeutics Limited AUD 37.91M 15.92M Dec/2025
Amarin USD 626.02M 23.87M Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
Biogen USD 9.19B 216.3M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Cipla INR 241.47B 7.71B Mar/2026
CSL USD 11.85B 1000K Dec/2025
Cytokinetics USD 839.46M 77.51M Mar/2026
Daiichi Sankyo JPY 2.1T 218.5B Dec/2025
Eli Lilly USD 54.84B 794M Mar/2026
Esperion Therapeutics USD 459.46M 3.11M Mar/2026
Geron USD 498.53M 21.74M Mar/2026
Grifols EUR 5.96B 316.31M Dec/2025
Halozyme Therapeutics USD 1B 177.83M Mar/2026
Heron Therapeutics USD 228.98M 9.08M Mar/2026
Ionis Pharmaceuticals USD 2.94B 52M Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Moderna USD 5.77B 774M Mar/2026
Nektar Therapeutics USD 266.27M 15.09M Dec/2025
Pfizer USD 42.82B 76M Mar/2026
PTC Therapeutics USD 2.25B 19.94M Mar/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 18.21B 187.3M Mar/2026
Sanofi EUR 30.16B 789M Mar/2026
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
United Therapeutics USD 2.87B 830.5M Mar/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025